Metropolis Healthcare Ltd. (IN:METROPOLIS)
:METROPOLIS
Want to see IN:METROPOLIS full AI Analyst Report?
Top Page
Metropolis Healthcare Ltd.
(METROPOLIS)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹601.00
▼(-68.86% Downside)
Action:Upgraded
Date:05/15/26
The score is primarily driven by solid financial performance—strong cash generation and a conservatively levered balance sheet—partly offset by margin/profitability volatility. Technicals are supportive but look overbought, and valuation is a meaningful headwind due to the high P/E and very low dividend yield.
Positive Factors
Conservative balance sheet
Leverage declined materially over multiple years and equity has grown with assets, giving the company durable financial flexibility. A low debt base supports capital expenditure, inorganic opportunities and resilience in downturns, reducing refinancing and liquidity risk long term.
Negative Factors
Profitability volatility
Operating margins and reported earnings have swung across years, leaving earnings quality uneven. Persistent margin volatility undermines forecasting, could limit reinvestment choices, and raises execution risk that modest top-line gains may not consistently translate into durable profit improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Leverage declined materially over multiple years and equity has grown with assets, giving the company durable financial flexibility. A low debt base supports capital expenditure, inorganic opportunities and resilience in downturns, reducing refinancing and liquidity risk long term.
Read all positive factors
Metropolis Healthcare Ltd. (METROPOLIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹107.45B
Dividend Yield0.21%
Average Volume (3M)3.90K
Price to Earnings (P/E)44.1
Beta (1Y)0.78
Revenue Growth23.64%
EPS Growth29.96%
CountryIN
Employees4,313
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)7.40
Shares Outstanding207,327,770
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio1.58
Price to Book (P/B)5.93
Price to Sales (P/S)5.45
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)14.35
Revenue Forecast (FY)₹18.92B
Metropolis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as...
How the Company Makes Money
Metropolis Healthcare primarily makes money by charging fees for diagnostic tests and related services. Its key revenue streams typically include: (1) business-to-consumer (B2C) testing, where individuals pay out-of-pocket or via insurance/third-p...
Metropolis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.04B | 16.46B | 13.31B | 12.08B | 11.48B | 12.28B |
| Gross Profit | 10.85B | 7.87B | 10.28B | 9.38B | 8.74B | 9.31B |
| EBITDA | 2.43B | 4.01B | 2.16B | 2.18B | 2.36B | 3.07B |
| Net Income | 1.52B | 1.90B | 1.45B | 1.28B | 1.43B | 2.14B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 21.38B | 18.67B | 15.55B | 15.02B | 15.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.18B | 2.03B | 1.18B | 1.24B | 1.20B | 1.81B |
| Total Debt | 0.00 | 2.32B | 2.04B | 1.97B | 2.66B | 3.79B |
| Total Liabilities | -13.35B | 6.13B | 5.33B | 4.56B | 5.11B | 6.42B |
| Stockholders Equity | 13.35B | 15.13B | 13.31B | 10.96B | 9.88B | 8.86B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.99B | 2.19B | 2.00B | 1.94B | 2.23B |
| Operating Cash Flow | 0.00 | 3.50B | 2.63B | 2.64B | 2.47B | 2.53B |
| Investing Cash Flow | 0.00 | -2.18B | -2.01B | -894.12M | 467.94M | -7.38B |
| Financing Cash Flow | 0.00 | -1.20B | -866.34M | -1.81B | -2.92B | 1.63B |
Metropolis Healthcare Ltd. Technical Analysis
Positive
1929.70
Price Trends
473.87
Positive
475.52
Positive
489.15
Positive
Market Momentum
15.24
Positive
56.83
Neutral
9.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Positive. The current price of 1929.7 is above the 20-day moving average (MA) of 506.70, above the 50-day MA of 473.87, and above the 200-day MA of 489.15, indicating a bullish trend. The MACD of 15.24 indicates Positive momentum. The RSI at 56.83 is Neutral, neither overbought nor oversold. The STOCH value of 9.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:METROPOLIS.
Metropolis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹279.63B | 41.73 | ― | 0.89% | 12.25% | 3.57% | |
73 Outperform | ₹75.51B | 34.04 | ― | 0.68% | 20.61% | 78.25% | |
72 Outperform | ₹107.45B | 44.11 | ― | 0.21% | 23.64% | 29.96% | |
72 Outperform | ₹20.07B | 21.88 | ― | 0.16% | 16.08% | 14.61% | |
71 Outperform | ₹130.36B | 52.62 | ― | 0.20% | 19.49% | 20.50% | |
58 Neutral | ₹18.25B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:METROPOLIS
Metropolis Healthcare Ltd.
518.25
112.36
27.68%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.45
-81.39
-12.64%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,668.05
269.21
19.25%
IN:THYROCARE
Thyrocare Technologies Ltd
474.40
159.24
50.53%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,269.00
340.87
36.73%
IN:VIMTALABS
Vimta Labs Limited
449.35
-42.40
-8.62%
Metropolis Healthcare Ltd. Corporate Events
Metropolis Healthcare Allots RSU Shares and Expands 2025 Stock Benefit Plans
May 13, 2026
Metropolis Healthcare’s Nomination and Remuneration Committee has approved the allotment of 4,200 equity shares at an exercise price of ₹2 each under its 2020 Restricted Stock Unit Plan, following vesting and exercise by eligible emplo...
Metropolis Healthcare Grants New Stock Benefits and Allots Shares Under Employee Plans
May 13, 2026
Metropolis Healthcare’s Nomination and Remuneration Committee has approved the allotment of 4,200 equity shares under its 2020 Restricted Stock Unit Plan at an exercise price of ₹2 per share to employees, with the new shares ranking pa...
Metropolis Healthcare Closes Trading Window Ahead of FY26 Results
Mar 31, 2026
Metropolis Healthcare Ltd. has announced that its trading window for designated persons and their immediate relatives will be closed from April 1, 2026, in line with its code of conduct and SEBI’s insider trading regulations. The window will...
Metropolis Healthcare Boosts Paid-Up Capital with 3-for-1 Bonus Share Issue
Mar 23, 2026
Metropolis Healthcare Ltd. has allotted 155,495,826 bonus equity shares of face value ₹2 each on March 23, 2026, issuing three fully paid shares for every one existing share to eligible shareholders as of the March 20, 2026 record date. Foll...
Metropolis Healthcare Shareholders Approve Bonus Share Issue via E-Voting
Mar 9, 2026
Metropolis Healthcare has secured shareholder approval via a postal ballot and remote e-voting to issue bonus shares, with the resolution passed by the requisite majority. The process was conducted electronically in line with Companies Act provisi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.